Definitive Healthcare (NASDAQ:DH) Shares Down 5.4% - Time to Sell?

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report)'s stock price fell 5.4% during mid-day trading on Friday . The company traded as low as $3.99 and last traded at $3.97. 87,938 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 802,908 shares. The stock had previously closed at $4.19.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DH. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. BTIG Research cut Definitive Healthcare from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group boosted their price target on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a report on Monday, May 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $5.10.

Definitive Healthcare Stock Performance

The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The stock has a 50-day moving average price of $3.58 and a 200-day moving average price of $3.64. The company has a market capitalization of $597.54 million, a price-to-earnings ratio of -0.92, a PEG ratio of 6.60 and a beta of 1.64.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The company had revenue of $59.19 million for the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The company's revenue was down 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 earnings per share. As a group, analysts forecast that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP increased its position in shares of Definitive Healthcare by 5,305.5% in the fourth quarter. Quantbot Technologies LP now owns 17,730 shares of the company's stock worth $73,000 after purchasing an additional 17,402 shares during the period. Wells Fargo & Company MN grew its stake in Definitive Healthcare by 27.4% during the fourth quarter. Wells Fargo & Company MN now owns 31,297 shares of the company's stock worth $129,000 after buying an additional 6,736 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Definitive Healthcare by 20.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock valued at $85,000 after buying an additional 3,496 shares during the period. Northern Trust Corp raised its position in shares of Definitive Healthcare by 3.2% in the 4th quarter. Northern Trust Corp now owns 497,279 shares of the company's stock valued at $2,044,000 after buying an additional 15,530 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Definitive Healthcare by 6.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company's stock worth $334,000 after acquiring an additional 4,748 shares during the period. Institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.